AGIO · Agios Pharmaceuticals, Inc.
$35.28
-0.69 (-1.92%)
At close · Jul 29
Market Cap
$2.14B
Shares
59.47M
Agios Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Agios Pharmaceuticals, Inc. (AGIO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$5.58M
−$91.81M
'22 Q2
22-08-04
·
$3.52M
−$81.75M
'22 Q3
22-11-03
·
$4.31M
$36.53M
'22 Q4
23-02-23
▲574.2%
$5.61M
−$81.02M
'23 Q1
23-05-04
▲20.2%
$6.71M
−$83.81M
'23 Q2
23-08-03
▲110.4%
$7.40M
−$91.32M
'23 Q3
23-11-02
▲64.8%
$7.10M
−$95.94M
'23 Q4
24-02-15
▲46%
$8.19M
−$81.55M
'24 Q1
24-05-02
▲28.4%
$8.62M
−$96.12M
'24 Q2
24-08-01
▲21.2%
$8.96M
$947.91M
'24 Q3
24-10-31
▲51.1%
$10.73M
−$96.52M
'24 Q4
25-02-13
▲6.6%
$8.73M
−$89.29M
'25 Q1
25-05-01
▲44.6%
$12.46M
−$112.02M
'25 Q2
25-07-31
▲43.7%
$12.88M
−$103.43M
'25 Q3
25-11-19
▲86.1%
$19.97M
−$108.04M
'25 Q4
26-02-12
LATEST
▲137.7%
$20.75M
−$99.11M
'26 Q1
26-04-29
Earnings call
FY26 · Q1
2026-04-29
Agios Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone
Sickle cell disease label expansion / sNDA
Tepofitinib / next-generation PK activator
Regulatory engagement with FDA
Revenue
$20.75M
▲ 137.7% YoY Diluted EPS
$-1.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Agios Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone
ACVESME/Agvesme Launch in Thalassemia
Sickle Cell Disease Opportunity (mitapivat)
Lower-Risk MDS Pipeline (AG-236)
Revenue
$19.97M*
▲ 86.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-19
Agios Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
PYRUKYND thalassemia U.S. launch
Pipeline (Tebapivat, AG-181, AG-236)
Global commercialization partnerships
Revenue
$12.88M
▲ 43.7% YoY Diluted EPS
$-1.78
▼ 111% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Agios Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone
Thalassemia PDUFA and indication expansion
Capital-efficient ex-U.S. partnerships
Financial position and capital allocation
Revenue
$12.46M
▲ 44.6% YoY Diluted EPS
$-1.93
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Agios Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone
PYRUKYND Franchise and Commercial Expansion
Thalassemia Regulatory Review and PDUFA
Tebapivat Pipeline in MDS and Sickle Cell
Revenue
$8.73M
▲ 6.6% YoY Diluted EPS
$-1.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Agios Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone
PYRUKYND franchise and commercial launches
Thalassemia regulatory progress
Pediatric PK deficiency (ACTIVATE-KIDS)
Revenue
$10.73M*
▲ 51.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Agios Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone
Mitapivat in thalassemia (sNDA submission and launch)
Sickle cell disease (RISE UP Phase 3)
PK deficiency (PYRUKYND commercial launch)
Revenue
$8.96M
▲ 21.2% YoY Diluted EPS
$16.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Agios Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone
Mitapivat in thalassemia (ENERGIZE/ENERGIZE-T)
Sickle cell disease (RISE UP)
Pediatric PK deficiency (ACTIVATE-kids T)
Revenue
$8.62M
▲ 28.4% YoY Diluted EPS
$-1.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Agios Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone
Mitapivat in thalassemia (ENERGIZE/ENERGIZE-T)
Ex-U.S. partnership strategy
Pipeline and clinical milestones
Revenue
$8.19M
▲ 46% YoY Diluted EPS
$-1.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Agios Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone
Mitapivat pipeline progress
Thalassemia opportunity
PK deficiency commercial launch
Revenue
$7.10M*
▲ 64.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Agios Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$7.40M
▲ 110.4% YoY Diluted EPS
$-1.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Agios Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$6.71M
▲ 20.2% YoY Diluted EPS
$-1.51
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Agios Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$5.61M
▲ 574.2% YoY Diluted EPS
$-1.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Agios Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$4.31M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Agios Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$3.52M
Diluted EPS
$-1.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Agios Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Revenue
$5.58M
Diluted EPS
$-1.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Agios Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$832,000
Diluted EPS
$-1.74
▼ 106.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Agios Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Revenue
$*
▼ 100% YoY Diluted EPS
$-1.74
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Agios Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-1.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Agios Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-1.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Agios Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$26.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Agios Pharmaceuticals, Inc. Q4 FY2020 Earnings Call
Revenue
$44.05M
▲ 24.3% YoY Diluted EPS
$-1.41
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Agios Pharmaceuticals, Inc. Q3 FY2020 Earnings Call
Revenue
$34.71M
▲ 33.4% YoY Diluted EPS
$-1.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Agios Pharmaceuticals, Inc. Q2 FY2020 Earnings Call
Revenue
$37.35M
▲ 42.4% YoY Diluted EPS
$-1.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Agios Pharmaceuticals, Inc. Q1 FY2020 Earnings Call
Revenue
$87.10M
▲ 188.1% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Agios Pharmaceuticals, Inc. Q4 FY2019 Earnings Call
Revenue
$35.44M
▲ 18.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–26 of 26 earnings calls
Key facts
CIK
1439222
CUSIP
00847X104
13F (30d)
61 filings
37 filers
Visit website
Investor relations